Inhaled Immunotherapy for Acute Respiratory Infections
October 7, 2021
Inhalon Doses First Patient in Phase 1 Study of Inhaled IN‑006 to Treat COVID-19 Read more
July 22, 2021
Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home Read more
July 16, 2021
Inhalon Biopharma Appoints Jeff Hutchins, Ph.D. as Chief Development Officer Read more
A randomized, double-blind, Phase 1 study of IN-006, an inhaled antibody treatment for COVID-19
Moench T, Botta L, Farrer B, Lickliter JD, Kang H, Park Y, Kim C, Hoke M, Brennan M, McSweeney M, Richardson Z, Whelan J, Cho JM, Lee SY, Faurot F, Hutchins J, Lai SK medRxiv Aug 2022.
Stable nebulization and muco-trapping properties of Regdanvimab/IN-006 supports its development as a potent, dose-saving inhaled therapy for COVID-19
McSweeney M, Stewart I, Richardson Z, Kang H, Park Y, Kim C, Tiruthani K, Wolf W, Schaefer A, Kumar P, Aurora H, Hutchins J, Cho J, Hickey A, Lee S, Lai SK, bioRxiv Feb 2022.
Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai SK, Advanced Drug Delivery Reviews, Feb 2021.